Market Overview

Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors

Share:
Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors
Related DRRX
The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel
FDA Decision Sends Pain Therapeutics Reeling
Durect In PSC: Is DUR-928 A Class Act? (Seeking Alpha)

DURECT Corporation (NASDAQ: DRRX) has had a rough few months since the failure of a Phase 3 trial for its formerly leading drug candidate.

Days after reporting top- and bottom-line quarterly beats, the biotech received support in the form of an upgrade from H.C. Wainwright. 

The Rating

H.C. Wainwright analyst Ed Arce upgraded Durect from Neutral to Buy with a $3.50 price target.

The Thesis

The rating was justified by multiple near-term catalysts and progress in Durect’s pipeline, Arce said in a Tuesday note. (See the analyst's track record here.) 

Durect is expected to release data this year on two open-label Phase 2a studies for its lead development asset, endogenous epigenetic regulator DUR-928 for primary sclerosing cholangitis and alcoholic hepatitis.

The firm also intends to initiate a Phase 2 study for psoriasis treatment, which Arce considers an entry point for investors. The analyst said he expects a positive readout.

“Importantly, we believe investor sentiment has now begun to shift to a positive bias, based on the broad preclinical and Phase 1 data set, and large commercial opportunity, of DUR-928,” Arce said. 

A second catalyst comes in the form of regulatory approvals on partnered assets. Indivior’s RBP-7000 for schizophrenia and Pain Therapeutics, Inc. (NASDAQ: PTIE)’s REMOXY ER to deter oxycodone abuse each have Prescription Drug User Fee Act dates for New Drug Applications in the second half of the year.

Price Action

Durect stock popped 20 percent premarket and was up 10.67 percent at $1.66 at the time of publication Tuesday afternoon. 

Related Links:

Pharma M&A Picks Up Momentum

The Companies That Led 2017's Biotech Rally

Latest Ratings for DRRX

DateFirmActionFromTo
Mar 2018H.C. WainwrightUpgradesNeutralBuy
Oct 2017Stifel NicolausDowngradesBuyHold
Oct 2017H.C. WainwrightDowngradesBuyNeutral

View More Analyst Ratings for DRRX
View the Latest Analyst Ratings

Posted-In: Ed Arce H.C. WainwrightAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (DRRX + PTIE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ETTXWedbushInitiates Coverage On19.0
WINGWedbushDowngrades0.0
BMYCitigroupDowngrades57.0
INTCNomuraUpgrades0.0
HRZNKeefe Bruyette & WoodsDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Vanguard Shifts Indexes On 3 ETFs Ahead Of Sector Changes

Amid Fragmented Pizza Market, Domino's Still Has Room To Grow